3 completed, 1 unknown. 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 3, Unknown 1 |
Follow Simcere Pharmaceutical Co., Ltd: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Crossover Study to Evaluate the Relative Bioavailability of Two Formulations of Deuterated Remdesivir Hydrobromide for Oral Suspension in Healthy Chinese Adults T-R (Test-Reference drug), R-T (Reference-Test drug) - Healthy Participants | Phase 1 | Completed | Simcere Pharmaceutical Co., Ltd | 48 | 2026-04-17 | 2026-10-23 |
| A Comparative Study of the Pharmacokinetics of SIM0718 Injection in Healthy Adult Subjects in China Rademikibart injection, CBP-201 injection - Healthy Adult Subjects | Phase 1 | Completed | Simcere Pharmaceutical Co., Ltd | 178 | 2024-11-28 | 2026-04-03 |
| A Study to Evaluate the Pharmacokinetics,Safety and Tolerability of Y-2 Sublingual Tablet in Healthy Adult Subjects Y-2 Sublingual Tablet, Placebo - Healthy | Phase 1 | Completed | Simcere Pharmaceutical Co., Ltd | 36 | 2023-09-06 | 2023-12-12 |
| Nocardia Rubra Cell Wall Skeleton (N-CWS) Plus HAIC, Lenvatinib and Tislelizumab in Treating Patients With Advanced HCC Nocardia rubra cell wall skeleton, Hepatic arterial infusion chemotherapy, Lenvatinib - Hepatocellular Carcinoma | Phase 1 | Unknown | Wan-Guang Zhang | 30 | 2022-09-01 | 2023-12-19 |
cell wall skeleton, Nocardia (1) · lenvatinib (1) · tislelizumab (1)
China (3) · United States (1)
David Han, MD (1) · Wan-guang Zhang, M.D. (1)